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Genetics of progressive renal failure in diabetic kidney disease.
Diabetic kidney disease is a microvascular complication that
is observed in a minority of patients with long-standing hyper-
glycemia. Diabetic nephropathy (DN) is associated with short-
ened patient survival, severe morbidity, and increased health
care costs. Unfortunately, the incidence rates of DN continue
to increase in Western societies, and DN is now the most com-
mon reported cause of end-stage renal disease in developed na-
tions. DN results from a complex interplay between inherited
and environmental factors. This article reviews the data that
support an inherited basis for susceptibility to DN by summa-
rizing familial aggregation studies, genome-wide linkage, and
population-based association analyses in diabetic and nondia-
betic kidney disease. Recent evidence linking genes involved in
the regulation of endothelial function with genetic predisposi-
tion to albuminuria is presented. The integration of carefully
designed genetic linkage and association studies with gene ex-
pression experiments in human and animal models of diabetic
kidney disease appear to offer great promise for detecting the
molecular mechanisms underlying susceptibility to DN.
One third of white patients with diabetes mellitus
(DM) will develop overt proteinuria, reduced glomeru-
lar filtration rate (GFR), and end-stage renal disease
(ESRD). The proportion of individuals developing se-
vere nephropathy is higher among diabetic African
Americans, Hispanic Americans, and Native Americans
[1]. Although microalbuminuria is recognized as a ma-
jor risk factor for premature cardiovascular disease and
progressive chronic kidney disease in type 1 and type 2 di-
abetic individuals, it also signifies endothelial dysfunction
with a heightened risk for cardiovascular disease in non-
diabetic hypertensive patients and in normotensives. Di-
abetic retinopathy, another microvascular complication,
develops over time in the vast majority of diabetic pa-
tients. In contrast, renal complications only develop in a
subset of diabetic patients despite chronically elevated
blood sugar, blood pressure, and serum lipids. The poor
correlation between glycemic and hypertension control
with development of diabetic nephropathy (DN) suggests
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that environmental factors are not the sole cause. Mount-
ing evidence supports the role of genetic factors in the
pathogenesis of DN.
FAMILIAL AGGREGATION OF DIABETIC AND
NONDIABETIC NEPHROPATHY
Familial aggregation of overt DN and diabetic ESRD
has been widely observed. Seaquist et al demonstrated
that 83% of the type 1 diabetic siblings of white probands
with DN had overt nephropathy. In contrast, only 17%
of the diabetic siblings of probands without nephropa-
thy (despite long durations of DM) developed overt DN
[2]. Similarly, Quinn et al [3] reported that the presence
of nephropathy in a diabetic was strongly influenced by
the degree of proteinuria in their diabetic sibling. A 72%
cumulative risk of nephropathy was observed in those
whose diabetic siblings had proteinuria, compared with a
25% cumulative risk in those having normoalbuminuric
siblings. The large difference observed in nephropathy
risk based on familial aggregation strongly suggests that
inherited factors are causative. Familial aggregation of
DN in type 1 DM and type 2 DM has been reported in
every study that has assessed for this risk factor, including
European [4, 5], Pima Indian [6], African American [7],
South American [8], Southeast Asian [9], and Indian pop-
ulations [10]. Familial aggregation of nondiabetic ESRD
has also been repeatedly observed [11], as has the cluster-
ing of diabetic and nondiabetic nephropathy within single
families [12]. Few topics in the renal literature demon-
strate such consistent results.
The heritability of urinary albumin excretion was
evaluated in type 2 diabetic Pima Indian and white
families. A heritability of 0.21 was observed for urine
albumin:creatinine ratio (ACR) in a segregation analy-
sis in 715 diabetic Pima families. This work supported
the existence of a major (Mendelian) gene contribut-
ing to albuminuria [13]. Similar results were reported in
white diabetic patients at the Joslin Diabetes Center [14].
The familial aggregation of urine ACR was again con-
firmed in white type 2 DM concordant siblings in the Di-
abetes Heart Study (DHS) [15]. The heritability of urine
ACR was 0.46 in 662 diabetic individuals from 310 DHS
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families (comprising 422 DM-concordant sibling pairs)
[15]. Age, gender, use of medicines affecting ACR, and
blood pressure contributed to less than 10% of the vari-
ation in urine ACR. The heritability of renal function
in the DHS (calculated with the Modification of Diet in
Renal Disease GFR equation) was 0.75 [15]. The pro-
portion of the variance in GFR that was attributable to
mean blood pressure, medication effect, and hemoglobin
A1C was 2%. Together, these reports strongly support
the presence of genes influencing albuminuria and renal
function in diabetic families.
GENOME WIDE LINKAGE STUDIES IN
DIABETIC AND NONDIABETIC NEPHROPATHY
Genome-wide scans in appropriate family collections
offer great hope for identifying the major genetic compo-
nents of DN. The advantage of the genome screen strat-
egy is the comprehensive evaluation of the entire genome,
because there is no a priori knowledge of the location of
putative DN susceptibility genes.
The first genome scan searching for nephropathy and
retinopathy loci was performed in 98 Pima Indian sibling
pairs concordant for DN [16]. The strongest evidence for
linkage was observed on chromosome 7q (maximum log
of the odds [LOD] score 2.7 at genetic marker D7S500),
with additional evidence for linkage on chromosomes 3
and 9 (also linked to retinopathy) and chromosome 20. A
discordant sibling-pair analysis in type 1 diabetes families
[17] reported a nephropathy linkage on chromosome 3 in
the region containing the angiotensin II type-1 receptor
gene. A detailed evaluation of the angiotensin II type-
1 receptor gene excluded a role for this gene in the 3q
linkage peak.
A genome scan of 18 large Turkish kindreds containing
multiple individuals with type 2 DN has been reported
[18]. A major linkage peak was observed on chromosome
18q using an autosomal dominant model for inheritance
of DN (LOD score 6.6 between markers D18S43 and
D18S50). Evaluation of these loci in Pima Indian families
confirmed evidence of linkage, despite the fact that the
original genome wide scan was not sensitive enough to
detect it.
We recently reported a genome scan for DN in 206
African American type 2 diabetic sibling pairs concor-
dant for severe diabetic kidney failure (ESRD or ad-
vanced DN) from 166 families [19]. In an initial analysis,
no LOD scores above 2.0 were detected. Multilocus in-
teraction analysis detected 6 additional loci (on chromo-
somes 7p, 12p, 14q, 16p, 18q, and 21q) with LOD scores
between 1.15 and 1.63. Ordered subset analyses were per-
formed to identify potentially homogeneous families for
detection of genetic linkage. Using ordered subset analy-
ses, African American families with the earliest mean age
at development of diabetes had evidence for a DN sus-
ceptibility locus on chromosome 18q (LOD 3.72 in 64%
of families).
The linkage peaks for DN observed on chromosomes
3q, 7q, and 18q overlap despite the genome scans being
performed in diverse populations, using different study
designs and methodologies. Linkage was identified on
chromosome 3q in white families with type 1 DN [17],
and type 2 DN in Pima Indians [16] and African Ameri-
cans [19]. The 18q linkage to DN was observed in Turkish
[18] and African American families and in an association
analysis in Pima Indians. The replication of results in-
creases the likelihood that these chromosomal locations
harbor DN genes.
The National Institutes of Health-sponsored Fam-
ily Investigation of Nephropathy and Diabetes (FIND)
study will soon complete a genome scan using single
nucleotide polymorphisms in more than 6000 individu-
als from multiply-affected DM families enriched for the
presence of overt DN or diabetic ESRD [20]. African
American, white, Hispanic American, and American In-
dian families are being recruited. The final FIND genome
scan will be performed with associated quantitative traits
(albuminuria, proteinuria, and GFR) as well as for the
presence or absence of overt DN. The FIND study should
have adequate power to determine whether DN suscep-
tibility alleles are consistent between ethnic groups.
The clustering of diabetic and nondiabetic ESRD in
families suggested that these diverse disorders might
share common susceptibility loci (i.e., renal failure genes
might exist that were independent of the presence of hy-
perglycemia or hypertension). However, genome scans
in large numbers of African American families with pre-
dominantly nondiabetic etiologies of ESRD [21] and all-
cause ESRD [22] failed to replicate the linked regions
observed in the diabetic ESRD genome scan [19]. Evi-
dence for linkage was observed on chromosomes 13q33.3
and 1q25.1 in both the nondiabetic ESRD and the all-
cause ESRD genome scans.
CANDIDATE GENE ASSOCIATION STUDIES
IN DN
Our current understanding of the pathophysiology of
DN suggests that complex interactions exist between
multiple pathways. These have been previously reviewed
[23–27] and include increased activity of a variety of
growth factors and cytokines (i.e., transforming growth
factor b , growth hormone, insulin-like growth factor 1,
vascular endothelial growth factor, and epidermal growth
factor); activation of protein kinase C isoforms; increased
release of renin, angiotensin, endothelin, and bradykinin;
formation of reactive oxygen species; increased for-
mation of advanced glycation end-products; increased
activity of the aldose reductase pathway; and abnormal-
ities in glucose transport mechanisms. These pathways
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likely interact to cause DN. Based on underlying biol-
ogy, researchers have studied functional candidate gene
polymorphisms that alter levels or activities within these
pathways. At present, little consistent evidence exists for
the contribution of these candidate genes to risk for DN.
The majority of candidate gene classes evaluated in DN
have been implicated in inflammatory processes. This re-
flects the general impression that inflammation plays a
key role in the genesis of diabetic complications. Microal-
buminuria is a hallmark of endothelial dysfunction, and it
represents a “pro-inflammatory” state. Therefore, we re-
cently examined the roles of two endothelial dysfunction-
related genes, endothelial nitric oxide synthase (NOS3)
and P-selectin, in predisposition to diabetic albuminuria.
ENDOTHELIAL NITRIC OXIDE SYNTHASE
The NOS3 gene is expressed by vascular endothelial
cells and variation in the NOS3 gene encoding endothe-
lial nitric oxide synthase alters nitric oxide production.
Endothelial dysfunction contributes to the development
of DN as a result of a decrease in production of active
nitric oxide. Therefore, the NOS3 gene on chromosome
7q35-36 would appear to be a strong candidate gene for
susceptibility to DN. NOS3 was also in the chromosome
region that was found to be linked with nephropathy in
type 2 diabetic Pima Indian families [16]. Only a sin-
gle polymorphism, T-786C in the promoter region, has
been reported to affect transcription by reducing pro-
moter activity [28]. In a case-control study of 347 type 1
DM patients, the -789C allele was more frequent in the
78 cases with advanced diabetic nephropathy than in the
74 cases with proteinuria or 195 control subjects free of
DN [29]. Another case control study demonstrated that
the frequency of the C allele was significantly increased
in hemodialysis patients with nondiabetic nephropathy
(N = 168) and with DN (N = 84), compared with healthy
controls (N = 187) [30]. These two studies suggested that
the progression of renal disease was influenced by the
T-786C polymorphism.
We examined the role of the T-786C polymorphism in
susceptibility to albuminuria in 590 white siblings from
230 type 2 DM families in the DHS [31]. This study
demonstrated that the -786C allele was associated with
increased ACR (31% increase in absolute level of ACR
for each additional copy of the -786C allele; P < 0.0001)
in a co-dominant inheritance mode. In support of this
finding, quantitative pedigree disequilibrium test analy-
ses revealed an excess transmission of the C allele to those
with higher levels of ACR (P = 6.25e−05).
P-SELECTIN
P-selectin, an adhesion molecule, is expressed on the
surface of activated platelets and vascular endothelial
cells. This adhesion molecule might play an important
role in the pathogenesis of atherosclerosis by mediat-
ing leukocyte “rolling” on the endothelium, promoting
the inflammatory process, and contributing to plaque
initiation and progression. Therefore, variation in the P-
selectin gene may account for a portion of one’s pre-
disposition to endothelial dysfunction and subsequent
microalbuminuria. Prior association studies suggested
that P-selectin gene polymorphisms impacted the risk of
myocardial infarction [32]. A role for the P-selectin gene
in DN and albuminuria was heretofore unknown.
We determined that Ser290Asn (S290N), a non-
synonymous polymorphism in exon 7 of the P-selectin
gene, was associated with an increased risk for the pres-
ence of albuminuria in DHS families (odds ratio, 1.71
for each 290Asn allele; P = 0.002) [33]. This association
appeared to be in a co-dominant inheritance mode. Hap-
lotype analyses revealed that haplotypes containing an
asparagine (N) codon trended toward association with
increasing degrees of albuminuria. Biologic mechanisms
underlying the associations of these haplotypes with the
risk of albuminuria have not yet been elucidated.
CONCLUSION
The evaluation of candidate genes underlying suscep-
tibility to DN has been a difficult task with inconsistent
results. This lack of replication was likely due to small
sample sizes, incomplete genetic dissection of the poly-
morphisms in candidate genes, moderate effect sizes, and
extensive genetic and phenotypic heterogeneity. Multi-
center initiatives, such as the FIND and Genetics of Kid-
ney Disease in Diabetes, will soon provide renewable
sources of DNA from large numbers of diabetic families.
Continued sequencing and analysis of the human genome
by the Human Genome Project [34, 35], the HapMap
project [36], and the Programs for Genomic Applications
project will allow better exploitation of genetic variation.
The technology for carrying out large-scale molecular ge-
netic studies is rapidly improving, which will soon enable
the performance of whole genome association studies.
Combining in vitro and in vivo functional studies in DN
with the results from population-based genetic analyses
is likely to further our understanding of the genetic basis
of DN. These analyses will have the potential to identify
genes producing susceptibility to DN and may lead to
novel treatment strategies to slow or prevent this devas-
tating complication of diabetes mellitus.
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